{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:14:17Z","timestamp":1784589257359,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019683","name":"Cole Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019683","id-type":"DOI","asserted-by":"crossref"}]},{"name":"SUR del DEC de la Generalitat de Catalunya"},{"name":"European Social Funds"},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","award":["003600"],"award-info":[{"award-number":["003600"]}],"id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","award":["003600"],"award-info":[{"award-number":["003600"]}],"id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse large B cell lymphoma (DLBCL) is successfully treated with combination immuno-chemotherapy, but relapse with resistant disease occurs in\u2009~\u200940% of patients. However, little is known regarding relapsed\/refractory DLBCL (rrDLBCL) genetics and alternative therapies. Based on findings from other tumors, we hypothesized that RAS-MEK-ERK signaling would be upregulated in resistant tumors, potentially correlating with mutations in RAS, RAF, or associated proteins. We analyzed mutations and phospho-ERK levels in tumor samples from rrDLBCL patients. Unlike other tumor types, rrDLBCL is not mutated in any Ras or Raf family members, despite having increased expression of p-ERK. In paired biopsies comparing diagnostic and relapsed specimens, 33% of tumors gained p-ERK expression, suggesting a role in promoting survival. We did find mutations in several Ras-associating proteins, including GEFs, GAPs, and downstream effectors that could account for increased ERK activation. We further investigated mutations in one such protein, RASGRP4. In silico modeling indicated an increased interaction between H-Ras and mutant RASGRP4. In cell lines, mutant RASGRP4 increased basal p-ERK expression and lead to a growth advantage in colony forming assays when challenged with doxorubicin. Relapsed\/refractory DLBCL is often associated with increased survival signals downstream of ERK, potentially corresponding with mutations in protein controlling RAS\/MEK\/ERK signaling.<\/jats:p>","DOI":"10.1038\/s41598-021-04736-0","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:03:22Z","timestamp":1642417402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mutated RAS-associating proteins and ERK activation in relapse\/refractory diffuse large B cell lymphoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Alexandre","family":"Benoit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bou-Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Guilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Mingyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Dmitrienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Estrada-Tejedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koren K.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"4736_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.semdp.2011.04.001","volume":"28","author":"C Schneider","year":"2011","unstructured":"Schneider, C., Pasqualucci, L. & Dalla-Favera, R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin. Diagn. Pathol. 28, 167\u2013177. https:\/\/doi.org\/10.1053\/j.semdp.2011.04.001 (2011).","journal-title":"Semin. Diagn. Pathol."},{"key":"4736_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8 (2018).","journal-title":"Nat. Med."},{"key":"4736_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313\u20132323. https:\/\/doi.org\/10.1056\/NEJMoa0802885 (2008).","journal-title":"N. Engl. J. Med."},{"key":"4736_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125, 22\u201332. https:\/\/doi.org\/10.1182\/blood-2014-05-577189 (2015).","journal-title":"Blood"},{"key":"4736_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","volume":"41","author":"B Bonavida","year":"2014","unstructured":"Bonavida, B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: Strategies to overcome resistance. Semin. Oncol. 41, 667\u2013677. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.08.006 (2014).","journal-title":"Semin. Oncol."},{"key":"4736_CR6","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1182\/blood-2008-09-177469","volume":"113","author":"NA Johnson","year":"2009","unstructured":"Johnson, N. A. et al. Diffuse large B-cell lymphoma: Reduced CD20 expression is associated with an inferior survival. Blood 113, 3773\u20133780. https:\/\/doi.org\/10.1182\/blood-2008-09-177469 (2009).","journal-title":"Blood"},{"key":"4736_CR7","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson, N. A. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3452\u20133459. https:\/\/doi.org\/10.1200\/JCO.2011.41.0985 (2012).","journal-title":"J. Clin. Oncol."},{"key":"4736_CR8","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","volume":"67","author":"AR Jazirehi","year":"2007","unstructured":"Jazirehi, A. R., Vega, M. I. & Bonavida, B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 67, 1270\u20131281. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2184 (2007).","journal-title":"Cancer Res."},{"key":"4736_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJM199708213370804","volume":"337","author":"A Ichikawa","year":"1997","unstructured":"Ichikawa, A. et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med. 337, 529\u2013534. https:\/\/doi.org\/10.1056\/NEJM199708213370804 (1997).","journal-title":"N. Engl. J. Med."},{"key":"4736_CR10","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","volume":"22","author":"RD Morin","year":"2016","unstructured":"Morin, R. D. et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin. Cancer Res. 22, 2290\u20132300. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2123 (2016).","journal-title":"Clin. Cancer Res."},{"key":"4736_CR11","doi-asserted-by":"publisher","first-page":"83294","DOI":"10.18632\/oncotarget.13065","volume":"7","author":"Y Cao","year":"2016","unstructured":"Cao, Y. et al. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget 7, 83294\u201383307. https:\/\/doi.org\/10.18632\/oncotarget.13065 (2016).","journal-title":"Oncotarget"},{"key":"4736_CR12","doi-asserted-by":"publisher","first-page":"86433","DOI":"10.18632\/oncotarget.13239","volume":"7","author":"HY Park","year":"2016","unstructured":"Park, H. Y. et al. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. Oncotarget 7, 86433\u201386445. https:\/\/doi.org\/10.18632\/oncotarget.13239 (2016).","journal-title":"Oncotarget"},{"key":"4736_CR13","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.4161\/cc.9.9.11483","volume":"9","author":"SL Abrams","year":"2010","unstructured":"Abrams, S. L. et al. The Raf\/MEK\/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9, 1781\u20131791. https:\/\/doi.org\/10.4161\/cc.9.9.11483 (2010).","journal-title":"Cell Cycle"},{"key":"4736_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bmcl.2014.11.076","volume":"25","author":"QH Liu","year":"2015","unstructured":"Liu, Q. H., Shi, M. L., Sun, C., Bai, J. & Zheng, J. N. Role of the ERK1\/2 pathway in tumor chemoresistance and tumor therapy. Bioorg. Med. Chem. Lett. 25, 192\u2013197. https:\/\/doi.org\/10.1016\/j.bmcl.2014.11.076 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"4736_CR15","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1182\/blood-2005-09-3926","volume":"107","author":"B Hoang","year":"2006","unstructured":"Hoang, B. et al. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 107, 4484\u20134490. https:\/\/doi.org\/10.1182\/blood-2005-09-3926 (2006).","journal-title":"Blood"},{"issue":"Suppl 2","key":"4736_CR16","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","volume":"16","author":"A De Luca","year":"2012","unstructured":"De Luca, A., Maiello, M. R., D\u2019Alessio, A., Pergameno, M. & Normanno, N. The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets 16(Suppl 2), S17-27. https:\/\/doi.org\/10.1517\/14728222.2011.639361 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"key":"4736_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10059-009-0143-7","volume":"28","author":"KS Lau","year":"2009","unstructured":"Lau, K. S. & Haigis, K. M. Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer. Mol. Cells 28, 315\u2013320. https:\/\/doi.org\/10.1007\/s10059-009-0143-7 (2009).","journal-title":"Mol. Cells"},{"key":"4736_CR18","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516. https:\/\/doi.org\/10.1056\/NEJMoa1103782 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4736_CR19","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305\u20132315. https:\/\/doi.org\/10.1056\/NEJMoa1014209 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4736_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","volume":"373","author":"E Tiacci","year":"2015","unstructured":"Tiacci, E. et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N. Engl. J. Med. 373, 1733\u20131747. https:\/\/doi.org\/10.1056\/NEJMoa1506583 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4736_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12964-019-0415-6","volume":"17","author":"L Zhu","year":"2019","unstructured":"Zhu, L. et al. The critical role of RasGRP4 in the growth of diffuse large B cell lymphoma. Cell Commun. Signal 17, 92. https:\/\/doi.org\/10.1186\/s12964-019-0415-6 (2019).","journal-title":"Cell Commun. Signal"},{"key":"4736_CR22","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","volume":"122","author":"RD Morin","year":"2013","unstructured":"Morin, R. D. et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122, 1256\u20131265. https:\/\/doi.org\/10.1182\/blood-2013-02-483727 (2013).","journal-title":"Blood"},{"key":"4736_CR23","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. U. S. A. 109, 3879\u20133884. https:\/\/doi.org\/10.1073\/pnas.1121343109 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"4736_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 171, 481\u2013494. https:\/\/doi.org\/10.1016\/j.cell.2017.09.027 (2017).","journal-title":"Cell"},{"key":"4736_CR25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291\u2013304. https:\/\/doi.org\/10.1016\/j.cell.2018.03.022 (2018).","journal-title":"Cell"},{"key":"4736_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.cell.2013.04.031","volume":"153","author":"R Fritsch","year":"2013","unstructured":"Fritsch, R. et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050\u20131063. https:\/\/doi.org\/10.1016\/j.cell.2013.04.031 (2013).","journal-title":"Cell"},{"key":"4736_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248\u2013249. https:\/\/doi.org\/10.1038\/nmeth0410-248 (2010).","journal-title":"Nat. Methods"},{"key":"4736_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-138645","volume":"136","author":"MS Patel","year":"2020","unstructured":"Patel, M. S. et al. Gene expression and epigenetic analysis in relapsed\/refractory diffuse large B cell lymphoma provides insights into evolution of treatment resistance to R-CHOP. Blood 136, 26\u201326. https:\/\/doi.org\/10.1182\/blood-2020-138645 (2020).","journal-title":"Blood"},{"key":"4736_CR29","doi-asserted-by":"publisher","first-page":"8135","DOI":"10.1074\/jbc.M111.320580","volume":"287","author":"M Zhu","year":"2012","unstructured":"Zhu, M., Fuller, D. M. & Zhang, W. The role of Ras guanine nucleotide releasing protein 4 in Fc epsilonRI-mediated signaling, mast cell function, and T cell development. J. Biol. Chem. 287, 8135\u20138143. https:\/\/doi.org\/10.1074\/jbc.M111.320580 (2012).","journal-title":"J. Biol. Chem."},{"key":"4736_CR30","doi-asserted-by":"publisher","first-page":"30508","DOI":"10.1074\/jbc.M111330200","volume":"277","author":"GW Reuther","year":"2002","unstructured":"Reuther, G. W. et al. RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. J. Biol. Chem. 277, 30508\u201330514. https:\/\/doi.org\/10.1074\/jbc.M111330200 (2002).","journal-title":"J. Biol. Chem."},{"key":"4736_CR31","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1038\/emboj.2012.167","volume":"31","author":"S Suire","year":"2012","unstructured":"Suire, S. et al. GPCR activation of Ras and PI3Kc in neutrophils depends on PLCb2\/b3 and the RasGEF RasGRP4. EMBO J. 31, 3118\u20133129. https:\/\/doi.org\/10.1038\/emboj.2012.167 (2012).","journal-title":"EMBO J."},{"key":"4736_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12185-009-0299-0","volume":"89","author":"N Watanabe-Okochi","year":"2009","unstructured":"Watanabe-Okochi, N. et al. Possible involvement of RasGRP4 in leukemogenesis. Int. J. Hematol. 89, 470\u2013481. https:\/\/doi.org\/10.1007\/s12185-009-0299-0 (2009).","journal-title":"Int. J. Hematol."},{"key":"4736_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.29002","author":"Y Vercoulen","year":"2017","unstructured":"Vercoulen, Y. et al. A Histidine pH sensor regulates activation of the Ras-specific guanine nucleotide exchange factor RasGRP1. Elife https:\/\/doi.org\/10.7554\/eLife.29002 (2017).","journal-title":"Elife"},{"key":"4736_CR34","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1182\/blood-2004-10-3916","volume":"105","author":"Y Zheng","year":"2005","unstructured":"Zheng, Y. et al. Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood 105, 3648\u20133654. https:\/\/doi.org\/10.1182\/blood-2004-10-3916 (2005).","journal-title":"Blood"},{"key":"4736_CR35","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1074\/jbc.M707042200","volume":"283","author":"GP Katsoulotos","year":"2008","unstructured":"Katsoulotos, G. P. et al. The Diacylglycerol-dependent translocation of ras guanine nucleotide-releasing protein 4 inside a human mast cell line results in substantial phenotypic changes, including expression of interleukin 13 receptor alpha2. J. Biol. Chem. 283, 1610\u20131621. https:\/\/doi.org\/10.1074\/jbc.M707042200 (2008).","journal-title":"J. Biol. Chem."},{"key":"4736_CR36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.intimp.2018.09.024","volume":"64","author":"H Qiu","year":"2018","unstructured":"Qiu, H. et al. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10\/STAT3 cascade. Int. Immunopharmacol. 64, 394\u2013400. https:\/\/doi.org\/10.1016\/j.intimp.2018.09.024 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"4736_CR37","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.3361","volume":"47","author":"M Krauthammer","year":"2015","unstructured":"Krauthammer, M. et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 47, 996\u20131002. https:\/\/doi.org\/10.1038\/ng.3361 (2015).","journal-title":"Nat. Genet."},{"key":"4736_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.20892\/j.issn.2095-3941.2016.0026","volume":"13","author":"W Liao","year":"2016","unstructured":"Liao, W. & Sharma, S. Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies. Cancer Biol. Med. 13, 277\u2013285. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0026 (2016).","journal-title":"Cancer Biol. Med."},{"key":"4736_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.9","volume":"49","author":"SY Cho","year":"2017","unstructured":"Cho, S. Y. et al. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Exp. Mol. Med. 49, e317. https:\/\/doi.org\/10.1038\/emm.2017.9 (2017).","journal-title":"Exp. Mol. Med."},{"key":"4736_CR40","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-09-4729","volume":"70","author":"D Yang","year":"2010","unstructured":"Yang, D. et al. RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype. Cancer Res. 70, 7905\u20137917. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4729 (2010).","journal-title":"Cancer Res."},{"key":"4736_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41419-019-1493-5","volume":"10","author":"D Izumi","year":"2019","unstructured":"Izumi, D. et al. TIAM1 promotes chemoresistance and tumor invasiveness in colorectal cancer. Cell Death Dis. 10, 267. https:\/\/doi.org\/10.1038\/s41419-019-1493-5 (2019).","journal-title":"Cell Death Dis."},{"key":"4736_CR42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13059-014-0432-0","volume":"15","author":"Y Jiang","year":"2014","unstructured":"Jiang, Y. et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol. 15, 432. https:\/\/doi.org\/10.1186\/s13059-014-0432-0 (2014).","journal-title":"Genome Biol."},{"key":"4736_CR43","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1158\/0008-5472.CAN-03-3500","volume":"64","author":"AR Jazirehi","year":"2004","unstructured":"Jazirehi, A. R., Vega, M. I., Chatterjee, D., Goodglick, L. & Bonavida, B. Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin\u2019s lymphoma B cells by Rituximab. Cancer Res. 64, 7117\u20137126. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3500 (2004).","journal-title":"Cancer Res."},{"key":"4736_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102505","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio, I. C., Mungo, E., Gazzano, E., Kopecka, J. & Riganti, C. ERK is a pivotal player of chemo-immune-resistance in cancer. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20102505 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"4736_CR45","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-14-1490","volume":"5","author":"E Chevet","year":"2015","unstructured":"Chevet, E., Hetz, C. & Samali, A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov. 5, 586\u2013597. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-1490 (2015).","journal-title":"Cancer Discov."},{"key":"4736_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.redox.2017.09.008","volume":"14","author":"SE Oh","year":"2018","unstructured":"Oh, S. E. & Mouradian, M. M. Cytoprotective mechanisms of DJ-1 against oxidative stress through modulating ERK1\/2 and ASK1 signal transduction. Redox Biol. 14, 211\u2013217. https:\/\/doi.org\/10.1016\/j.redox.2017.09.008 (2018).","journal-title":"Redox Biol."},{"key":"4736_CR47","first-page":"1607","volume":"127","author":"C Pierro","year":"2014","unstructured":"Pierro, C., Cook, S. J., Foets, T. C., Bootman, M. D. & Roderick, H. L. Oncogenic K-Ras suppresses IP3-dependent Ca2+ release through remodelling of the isoform composition of IP3Rs and ER luminal Ca2+ levels in colorectal cancer cell lines. J. Cell Sci. 127, 1607\u20131619 (2014).","journal-title":"J. Cell Sci."},{"key":"4736_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106\u2013109. https:\/\/doi.org\/10.1038\/nature10189 (2011).","journal-title":"Nature"},{"key":"4736_CR49","doi-asserted-by":"publisher","first-page":"7430","DOI":"10.1158\/0008-5472.CAN-14-1439","volume":"74","author":"S Tao","year":"2014","unstructured":"Tao, S. et al. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 74, 7430\u20137441. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1439 (2014).","journal-title":"Cancer Res."},{"key":"4736_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151638","volume":"11","author":"S Zhou","year":"2016","unstructured":"Zhou, S. et al. CD117+ dendritic and mast cells are dependent on RasGRP4 to function as accessory cells for optimal natural killer cell-mediated responses to lipopolysaccharide. PLoS ONE 11, e0151638. https:\/\/doi.org\/10.1371\/journal.pone.0151638 (2016).","journal-title":"PLoS ONE"},{"key":"4736_CR51","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.4049\/jimmunol.175.11.7179","volume":"175","author":"JJ Coughlin","year":"2005","unstructured":"Coughlin, J. J., Stang, S. L., Dower, N. A. & Stone, J. C. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J. Immunol. 175, 7179\u20137184. https:\/\/doi.org\/10.4049\/jimmunol.175.11.7179 (2005).","journal-title":"J. Immunol."},{"key":"4736_CR52","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/JLB.2HI0918-359RR","volume":"106","author":"S Suire","year":"2019","unstructured":"Suire, S. et al. Frontline science: TNF-alpha and GM-CSF1 priming augments the role of SOS1\/2 in driving activation of Ras, PI3K-gamma, and neutrophil proinflammatory responses. J. Leukoc Biol. 106, 815\u2013822. https:\/\/doi.org\/10.1002\/JLB.2HI0918-359RR (2019).","journal-title":"J. Leukoc Biol."},{"key":"4736_CR53","doi-asserted-by":"publisher","first-page":"R154","DOI":"10.1186\/ar3470","volume":"13","author":"T Hashimoto","year":"2011","unstructured":"Hashimoto, T. et al. Aberrant splicing of the hRasGRP4 transcript and decreased levels of this signaling protein in the peripheral blood mononuclear cells in a subset of patients with rheumatoid arthritis. Arthritis Res. Ther. 13, R154. https:\/\/doi.org\/10.1186\/ar3470 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"4736_CR54","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/art.38924","volume":"67","author":"M Kono","year":"2015","unstructured":"Kono, M. et al. Ras guanine nucleotide-releasing protein 4 is aberrantly expressed in the fibroblast-like synoviocytes of patients with rheumatoid arthritis and controls their proliferation. Arthritis Rheumatol. 67, 396\u2013407. https:\/\/doi.org\/10.1002\/art.38924 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"4736_CR55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"J-P Ryckaert","year":"1977","unstructured":"Ryckaert, J.-P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327\u2013341. https:\/\/doi.org\/10.1016\/0021-9991(77)90098-5 (1977).","journal-title":"J. Comput. Phys."},{"key":"4736_CR56","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N\u22c5log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089\u201310092. https:\/\/doi.org\/10.1063\/1.464397 (1993).","journal-title":"J. Chem. Phys."},{"key":"4736_CR57","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/nature07187","volume":"455","author":"H Rehmann","year":"2008","unstructured":"Rehmann, H. et al. Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B. Nature 455, 124\u2013127. https:\/\/doi.org\/10.1038\/nature07187 (2008).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04736-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:27:20Z","timestamp":1669321640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04736-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4736"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04736-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"779"}}